[1]谢静远,杨茂,郭卉.新型冠状病毒肝损伤机制探讨[J].医学争鸣,2021,(02):59-61.[doi:10.13276/j.issn.1674-8913.2021.02.012]
 XIE Jingyuan,YANG Mao,GUO Hui.Mechanism of liver injury in patients with COVID-19[J].,2021,(02):59-61.[doi:10.13276/j.issn.1674-8913.2021.02.012]
点击复制

新型冠状病毒肝损伤机制探讨

参考文献/References:

[1] HUANG C, WANG Y, LI X, et al. Clinical features ofpatients infected with 2019 novel coronavirus in Wuhan,China[J]. Lancet, 2020, 395(10223):497-506.
[2] GUAN W, NI Z, HU Y, et al. Clinical characteristics of2019 novel coronavirus infection in China[J]. N Engl J Med,2020, 22(3):2583-2587.
[3] CHEN N, ZHOU M, DONG X, et al. Epidemiological andclinical characteristics of 99 cases of 2019 novel coronaviruspneumonia in Wuhan, China: a descriptive study[J]. Lancet,2020, 395(10223):507-513.
[4] WANG D, HU B, HU C, et al. Clinical characteristics of138 hospitalized patients with 2019 novel coronavirusinfectedpneumonia in Wuhan, China[J]. JAMA, 2020,323(11):1061-1069.
[5] ZHU N, ZHANG D, WANG W, et al. A novel coronavirusfrom patients with pneumonia in China, 2019[J]. New Engl JMed, 2020, 382(8):727-733.
[6] HOFFMANN M, KLEINE-WEBER H, SCHROEDER S, etal. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2and is blocked by a clinically-proven protease inhibitor[J].Cell, 2020, 181(2):271-280.
[7] 杨湛, 许敏, 易俊卿, 等. 严重急性呼吸综合征肝损伤的临床特征[J]. 中华传染病杂志, 2003, 21(4):246-248.
[8] CHAU T N, LEE K C, YAO H, et al. SARS-associated viralhepatitis caused by a novel coronavirus: report of threecases[J]. Hepatology, 2004, 39(2):302-310.
[9] HOLSHUE M L, DEBOLT C, LINDQUIST S, et al. Firstcase of 2019 novel coronavirus in the United States[J]. NEngl J Med, 2020, 382(10):929-936.
[10] CHAI X, HU L, ZHANG Y, et al. Specific ACE2 expressionin cholangiocytes may cause liver damage after 2019-nCoVinfection[J]. BioRxiv, 2020. Online ahead of print. DOI:10.1101/2020.02.03.931766.
[11] 关贵文, 高林, 王建文, 等. 新型冠状病毒感染肺炎患者肝酶异常的机制探究[J]. 中华肝脏病杂志, 2020,28(2):100-106.
[12] SHEN T, LIU Y, SHANG J, et al. Incidence and etiologyof drug-induced liver injury in mainland China[J].Gastroenterology, 2019, 156(8):2230-2241.
[13] 国家卫生健康委员会医政医管局.《 新型冠状病毒肺炎诊疗方案(试行第七版)》. 国卫办医函(2020)184号(2020-03-04). http://health.people.com.cn/n1/2020/0304/c14739-31616706.html.
[14] 叶小文, 何冬黎, 程万清. 洛匹那韦/利托那韦临床应用概述[J/OL]. 中国医院药学杂志(2020-09-04). http://kns.cnki.net/kcms/detail/42.1204.r.20200228.1134.002.html.
[15] 李洋, 赵立. 阿比多尔抗呼吸道病毒的药理作用与体外和体内疗效研究现状[J]. 中国临床药理学杂志, 2019,35(17):1964-1968.
[16] 陈丽坪, 吴燕, 金澄滔, 等. 新型冠状病毒肺炎患者抗病毒治疗的药学监护:基于试行第七版诊疗方案[J]. 中国现代应用药学, 2020, 37(5):549-554.
[17] 贾海盼, 宋婧, 王丽, 等. 氯喹抗冠状病毒的作用及其安全性研究进展[J]. 中国药理学与毒理学杂志, 2020,34(4):272-277.
[18] 中国医师协会消化医师分会, 中华医学会肝病学分会.新型冠状病毒肺炎合并肝脏损伤的预防及诊疗方案[J].中华肝脏病杂志, 2020, 28(3):217-221.
[19] 李元元, 王立峰, 耿华, 等. 自身免疫性肝病患者外周血淋巴细胞亚群的频率变化及临床意义[J]. 临床肝胆病杂志, 2014, 30(5):409-412.
[20] 梁志清, 吴健林, 吴继周, 等. 机体免疫状态对慢性乙肝患者HBsAg和HBVDNA水平的影响[J]. 内科, 2009, 4(6):852-854.

相似文献/References:

[1]杨屹,王作仁,屈波,等.兔骨髓来源肝细胞修复射频消融肝损伤[J].医学争鸣,2008,(23):2156.
 YANG Yi,WANG Zuo Ren,QU Bo,et al.Repair of radiofrequency ablation liver injury by rabbit bone marrow derived hepatocytes[J].,2008,(02):2156.
[2]朱志云,李凌,叶纪录.硫普罗宁在严重脓毒血症与感染性休克中的保护肝脏作用[J].医学争鸣,2008,(20):3.
[3]张光发,叶雯,林涵真.闭合性肝损伤162例临床分析[J].医学争鸣,2007,(17):1572.
[4]于洪升,吴琍,王卓敏,等.低剂量辐射对环磷酰胺致肝功能损伤的影响[J].医学争鸣,2007,(06):574.
[5]杨屹,张明宇,屈波,等.射频肝损伤血清诱导兔骨髓干细胞向肝细胞样分化[J].医学争鸣,2008,(12):1100.
 YANG Yi,ZHANG Ming Yu,QU Bo,et al.Differentiation of mesenchymal stem cells into hepatocytelike cells induced by serum after radiofrequency ablation injury of liver[J].,2008,(02):1100.
[6]李艳超,白万柱,端川勉.潜在的神经侵袭特性可能是新型冠状病毒肺炎患者呼吸窘迫的原因之一[J].医学争鸣,2020,(01):7.[doi:10.13276/j.issn.1674-8913.2020.01.002 ]
 LI Yanchao,BAI Wanzhu,Tsutomu Hashikawa.Potential neuroinvasion may be one cause of respiratory distress in COVID-19 patients[J].,2020,(02):7.[doi:10.13276/j.issn.1674-8913.2020.01.002 ]
[7]林 真.胆碱酯酶激动剂用于新型冠状病毒肺炎辅助治疗的尝试[J].医学争鸣,2020,(01):15.[doi:10.13276/j.issn.1674-8913.2020.01.004 ]
 LIN Zhen.An attempt to use cholinesterase activators for assistant treatment of COVID-19[J].,2020,(02):15.[doi:10.13276/j.issn.1674-8913.2020.01.004 ]
[8]尚昱志,陈秋霞,方 刚,等.壮医五法预防新型冠状病毒肺炎[J].医学争鸣,2020,(02):7.[doi:10.13276/j.issn.1674-8913.2020.02.002]
 SHANG Yuzhi,CHEN Qiuxia,FANG Gang,et al.Five methods of Zhuang medicine’s epidemic prevention applied to corona virus disease 2019[J].,2020,(02):7.[doi:10.13276/j.issn.1674-8913.2020.02.002]
[9]张佳乐,杨 莉,鲜天才,等.艾灸防控新型冠状病毒肺炎的思路探讨[J].医学争鸣,2020,(02):10.[doi:10.13276/j.issn.1674-8913.2020.02.003]
 ZHANG Jiale,YANG Li,XIAN Tiancai,et al.Thoughts and methods of moxibustion for prevention and control of COVID-19[J].,2020,(02):10.[doi:10.13276/j.issn.1674-8913.2020.02.003]
[10]李代文,蒲 静,赵洁琨,等.五音疗法干预新型冠状病毒肺炎隔离人员情志的理论探讨[J].医学争鸣,2020,(02):15.[doi:10.13276/j.issn.1674-8913.2020.02.004]
 LI Daiwen,PU Jing,ZHAO Jiekun,et al.Theoretical study on five tone therapy for emotions of isolated people during the COVID-19 epidemic[J].,2020,(02):15.[doi:10.13276/j.issn.1674-8913.2020.02.004]
[11]谢静远,杨茂,郭卉.新型冠状病毒肝损伤机制探讨[J].医学争鸣,2021,(预出版):1.[doi:10.1101/2020.02.03.931766]
 XIE Jingyua n,YANG Mao,GUO Hui.Mechanism of liver injury in patients with COVID-19[J].,2021,(02):1.[doi:10.1101/2020.02.03.931766]

备注/Memo

通信作者:杨 茂。Tel:13821776022,E-mail:matchym@126.com
作者简介:谢静远。硕士生(导师郭 卉)。研究方向:肝病诊断与治疗。Tel:15202227913,E-mail:2974309004@qq.com

更新日期/Last Update: 2021-05-01